Alafair Biosciences Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
44
- Latest Deal Type
-
Debt - PPP
- Investors
-
8
Alafair Biosciences General Information
Description
Developer of biomaterials and biomedical devices designed to improve patient care by enhancing internal wound healing. The company's devices facilitate improved tendon gliding during the healing cascade by forming a permeable gelatinous layer around the tissue, which reduces surface-to-surface friction and inflammation, which is usually observed postoperatively, enabling medical practitioners to manage and protect tendon injuries in patients with no substantial loss of tendon tissue.
Contact Information
Website
www.alafairbiosciences.comCorporate Office
- 6101 West Courtyard Drive
- Suite 1-225
- Austin, TX 78730
- United States
Corporate Office
- 6101 West Courtyard Drive
- Suite 1-225
- Austin, TX 78730
- United States
Alafair Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Debt - PPP | 30-Apr-2020 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B) | 18-Apr-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A1) | 09-Aug-2016 | Completed | Startup | |||
| 7. Grant | 22-May-2014 | Completed | Startup | |||
| 6. Early Stage VC | 10-Sep-2013 | Completed | Startup | |||
| 5. Grant | 01-Jan-2013 | Completed | Startup | |||
| 4. Early Stage VC (Series AA) | 01-Nov-2011 | Completed | Startup | |||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Accelerator/Incubator | 01-Jan-2011 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2011 | Completed | Startup |
Alafair Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | ||||||||
| Series AA1 | 296,117 | $0.000100 | $1.77 | $1.77 | 1x | $1.77 | 3.07% | |
| Series AA | 633,143 | $0.000100 | $1.4 | $1.4 | 1x | $1.4 | 6.55% |
Alafair Biosciences Comparisons
Industry
Financing
Details
Alafair Biosciences Competitors (16)
One of Alafair Biosciences’s 16 competitors is CartiHeal, a Formerly VC-backed company based in Kfar Saba, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CartiHeal | Formerly VC-backed | Kfar Saba, Israel | ||||
| Compedica | Venture Capital-Backed | Wyboston, United Kingdom | ||||
| Reapplix | Venture Capital-Backed | Birkerod, Denmark | ||||
| Mölnlycke Health Care | Private Equity-Backed | Mölndal, Sweden | ||||
| Spine Wave | Venture Capital-Backed | Shelton, CT |
Alafair Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alafair Biosciences Patents
Alafair Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260027265-A1 | Sodium alginate and hyaluronic acid blended hydrogel matrix | Pending | 29-Jul-2024 | ||
| US-20260273140-A1 | Sodium alginate and hyaluronic acid blended hydrogel matrix | Pending | 29-Jul-2024 | ||
| US-20260315661-A1 | Sodium alginate and hyaluronic acid blended hydrogel matrix | Pending | 29-Jul-2024 | ||
| WO-2026030096-A1 | Sodium alginate and hyaluronic acid blended hydrogel matrix | Pending | 29-Jul-2024 | ||
| WO-2026030096-A8 | Sodium alginate and hyaluronic acid blended hydrogel matrix | Pending | 29-Jul-2024 | A61L27/26 |
Alafair Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alafair Biosciences Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ATP Fund | Venture Capital | Minority | ||
| UT Horizon Fund | Venture Capital | Minority | ||
| Texas Emerging Technology Fund | Venture Capital | Minority | ||
| National Institute of General Medical Sciences | Government | |||
| TEXO Ventures | Venture Capital | Minority |
Alafair Biosciences FAQs
-
When was Alafair Biosciences founded?
Alafair Biosciences was founded in 2011.
-
Where is Alafair Biosciences headquartered?
Alafair Biosciences is headquartered in Austin, TX.
-
What is the size of Alafair Biosciences?
Alafair Biosciences has 44 total employees.
-
What industry is Alafair Biosciences in?
Alafair Biosciences’s primary industry is Therapeutic Devices.
-
Is Alafair Biosciences a private or public company?
Alafair Biosciences is a Private company.
-
What is Alafair Biosciences’s current revenue?
The current revenue for Alafair Biosciences is .
-
How much funding has Alafair Biosciences raised over time?
Alafair Biosciences has raised $10.5M.
-
Who are Alafair Biosciences’s investors?
ATP Fund, UT Horizon Fund, Texas Emerging Technology Fund, National Institute of General Medical Sciences, and TEXO Ventures are 5 of 8 investors who have invested in Alafair Biosciences.
-
Who are Alafair Biosciences’s competitors?
CartiHeal, Compedica, Reapplix, Mölnlycke Health Care, and Spine Wave are some of the 16 competitors of Alafair Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
